GlassScriptPhysician profile
Stefan T Tachev
NPI 1295778108
$3,683.13
in general payments reported to CMS, 2019-2025
26 companies · $1,043 in 2025
The $1,043 reported for 2025 was more than what 79% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $713 · 2020: $58.10 · 2021: $205 · 2022: $372 · 2023: $583 · 2024: $710 · 2025: $1,043.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,271 · Education: $63.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.13 |
| Education | $63.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $584.33 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $319.89 | 2022-2025 | |
| Amgen INC. | $284.92 | 2019-2025 | Tavneos, Uplizna, Parsabiv |
| Lilly USA, LLC | $261.49 | 2023-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $245.95 | 2019-2025 | Ultomiris |
| Vifor Pharma, INC. | $234.52 | 2019-2025 | Veltassa |
| Mallinckrodt Hospital Products INC. | $226.77 | 2020-2025 | Acthar |
| Travere Therapeutics, INC. | $183.90 | 2024-2025 | Filspari |
| Otsuka America Pharmaceutical, INC. | $182.72 | 2019-2025 | Jynarque |
| Glaxosmithkline, LLC. | $176.58 | 2021-2024 | Benlysta, Jesduvroq |
| Novartis Pharmaceuticals Corporation | $176.45 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $98.85 | 2021-2025 | Rayaldee |
| Fresenius USA Marketing, INC. | $98.65 | 2021-2023 | Velphoro |
| Ardelyx, INC. | $91.11 | 2025 | Ibsrela |
| Akebia Therapeutics INC | $85.64 | 2022-2025 | Auryxia, Vafseo |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $83.01 | 2022-2023 | Purified Cortrophin Gel |
| Novo Nordisk INC | $72.70 | 2023-2025 | Ozempic, Rybelsus |
| Calliditas Therapeutics US INC. | $60.80 | 2025 | Tarpeyo |
| Takeda Pharmaceuticals U.S.A., INC. | $55.29 | 2022-2023 | Gattex |
| Horizon Therapeutics Plc | $36.28 | 2019-2021 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $29.58 | 2019 | |
| Genzyme Corporation | $25.71 | 2023 | |
| Shire North American Group INC | $20.66 | 2019 | |
| Scpharmaceuticals INC. | $18.50 | 2025 | |
| Mallinckrodt Enterprises LLC | $16.92 | 2019 | |
| Genentech USA, INC. | $11.91 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stefan Tachev listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.